On Thursday, in the course of current trade, Shares of Barrick Gold Corporation (NYSE:ABX), dropped -2.67%, and is now trading at $11.67, as gold prices dropped to a one-month low.
U.S. gold futures for August delivery were down 0.8% to $1,175.50 an ounce Thursday afternoon after hitting a one-month low of $1,174.90 an ounce earlier in the day.
Gold prices were falling ahead of the U.S. jobs report on Friday, according to Reuters. The U.S. Federal Reserve may soon raise interest rates for the first time nearly a decade depending on the data in the report, according to the news service.
Barrick Gold Corporation produces and sells gold and copper. The company is also involved in exploration and mine development activities. It conducts mining, development and exploration, and other activities in various countries, counting the United States, Canada, Australia, Argentina, Chile, Peru, the Dominican Republic, Papua New Guinea, Tanzania, Zambia, and Saudi Arabia.
During an Afternoon trade, Shares of The Hartford Financial Services Group, Inc. (NYSE:HIG), dipped -0.96%, and is now trading at $41.25.
The Hartford Financial Services Group, and Major League Baseball (MLB) declared a multi-year sponsorship that will make The Hartford an “Official Sponsor of Major League Baseball” and the exclusive business insurance, homeowners insurance and employee benefits partner of MLB. The sponsorship comprises the presenting sponsorship of the Reliever of the Year Awards and a partnership with legendary closer Mariano Rivera.
The Hartford will be the presenting sponsor of the American and National League Reliever of the Year Awards, named after MLB greats Mariano Rivera and Trevor Hoffman. Given out at the end of the regular season, this award recognizes the most outstanding relief pitchers of the season in each league. Hoffman will also appear in the company’s advertising.
The Hartford Financial Services Group, Inc., through its auxiliaries, provides insurance and financial services to individual and business customers primarily in the United States. The company’s Commercial Lines segment offers workers compensation, property, automobile, marine, umbrella, liability, and livestock coverages, in addition to customized insurance products and risk administration services, counting professional liability, bond, and specialty casualty coverages.
Shares of Whiting Petroleum Corp. (NYSE:WLL), during its Thursday’s current trading session fell -3.63%, and is now trading at $32.16.
Whiting Petroleum Corporation, declared that it has commenced an offer to exchange all of its outstanding, unregistered 6.25% Senior Notes due 2023 (the “Original Notes”) for new, registered 6.25% Senior Notes due 2023 (the “New Notes”).
The terms of the New Notes to be issued in the exchange offer are substantially identical to those of the Original Notes, except that the New Notes will not have securities law transfer restrictions, and the registration rights regarding the Original Notes and the New Notes will not provide for the payment of additional interest under circumstances regarding the timing of the exchange offer.
The exchange offer will expire at 5:00 p.m. New York City time, on July 1, 2015, unless extended by Whiting Petroleum Corporation. Valid tenders of the Original Notes must be made, and may be withdrawn at any time, before the exchange offer expires.
Whiting Petroleum Corporation, an independent oil and gas company, acquires, explores, develops, and produces crude oil, natural gas liquids, and natural gas in the Rocky Mountains and Permian Basin regions of the United States. It sells oil and gas to end users, marketers, and other purchasers.
Finally, Antares Pharma Inc. (NASDAQ:ATRS), lost -2.61% Thursday.
Antares Pharma, declared that it has received a written update from the U.S. Food and Drug Administration (FDA) related to its clinical development program for QuickShot® Testosterone (QS T) that the Company believes is consistent with its formerly revealed interpretation of the advice letter received from FDA in January 2015. As formerly revealed, the Company received an advice letter from FDA in January 2015 regarding various clinical, CMC (Chemistry, Manufacturing and Controls) and user study submissions made by the Company through November 2014, and the Company responded to that advice letter in March 2015. The Company believes that with the update just received from FDA, there is an agreed upon path forward for the completion of an additional study to support the filing of a New Drug Application for QS T. Based on the number of subjects in previous studies and in the current ongoing phase 3 study, the Company will need about 70 additional subjects exposed to QS T for six months, resulting in about 350 subjects exposed to QS T, with 200 subjects exposed for six months and 100 subjects exposed for a year. The Company is now finalizing the protocol for the study and anticipates to initiate the trial in the third quarter of 2015.
Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company’s injection products comprise OTREXUP, a pre-filled methotrexate syringe with Vibex self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Tjet/Zomajet, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
